A. Cook

发表

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

R. Laing, M. Parmar, M. Sydes, 2016, The Lancet.

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness

Matthew R. Sydes, Duncan B. McLaren, Eleftherios Sideris, 2018, European urology oncology.

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array

J. R. Wilson, David M. Holden, P. W. Foster, 2016, British Journal of Cancer.

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

C. R. Leemans, C. McConkey, T. Roques, 2019, The Lancet.

Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial.

S. Bhide, K. Harrington, T. Roques, 2021, European journal of cancer.

Results of a randomized phase III study of dysphagia-optimized intensity modulated radiotherapy (Do-IMRT) versus standard IMRT (S-IMRT) in head and neck cancer.

S. Bhide, T. Roques, C. Nutting, 2020 .

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer ( DeESCALaTE HPV )

C. McConkey, S. Whitaker, J. Buter, 2018 .

Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004)

S. Bhide, K. Harrington, C. Nutting, 2018, European journal of cancer.

LBA4 Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol

M. Sydes, C. Parker, N. James, 2021, Annals of Oncology.

Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.

S. Bhide, T. Roques, C. Nutting, 2023, The Lancet. Oncology.

Phase 4 Multinational Multicenter Retrospective and Prospective Real-World Study of Nivolumab in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck

E. Winquist, R. Metcalf, B. Bennett, 2023, Cancers.

LBA9 Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031)

M. Parmar, M. Sydes, C. Parker, 2022, Annals of Oncology.

in and metastatic sensitive : long-term results

D. Dearnaley, S. Gibbs, A. Zarkar, 2019 .